Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 6Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Advanced Solid Tumour 3Small Cell Lung Carcinoma 2Recurrence 2Multiple Myeloma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Breast Cancer 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroma 1Neoplasms 1Neoplasm Metastasis 1Multiple Sclerosis 1Lung Neoplasms 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Idiopathic Pulmonary Fibrosis 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Depression 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Blast Crisis 1

Interventions

Dexamethasone 46Lenalidomide 30Bortezomib 24daratumumab 23pomalidomide 20Cyclophosphamide 16carfilzomib 15Specimen Handling 14Biopsy 14Calcium Dobesilate 12isatuximab 11Magnetic Resonance Spectroscopy 10talquetamab 9Melphalan 8iberdomide 7fludarabine 7belantamab mafodotin 6tocilizumab 5selinexor 5dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5X-Rays 5fludarabine phosphate 4elotuzumab 4Sirolimus 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × Injections × 30 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡